Lenvatinib plus pembrolizumab demonstrated antitumor activity in advanced melanoma after prior anti-programmed cell death protein or ligand 1 [PD-(L)1] therapy in LEAP-004. Here, we report results from LEAP-003 (NCT03820986) which evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in unresectable advanced melanoma.
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma☆
Annals of Oncology | | A. Arance, M.-A. Berciano-Guerrero, J. Guo, M.S. Carlino, P.A. Ascierto, M. Burotto, L. Mortier, P. Queirolo, V. Chiarion-Sileni, J. Schachter, X. Zhang, J. Martin-Liberal, M. Del Vecchio, C.E. Okpara, C. Dutcus, J. Zhang, S.J. Diede, T. Neff, G.V. Long
Topics: skin-cancer, immunotherapy, clinical-trials, research